Résumé:
Emerging machine learning (ML) techniques have the potential to
greatly improve rare disease (RDs) research and treatment. The use of artificial intelligence (AI)
technologies can be especially advantageous for the study of RDs, which are a diverse group of diseases
that impact a small percentage of the whole population and significantly underrepresented in basic and
clinical research. The difficulties faced by RDs (such as small patient population, geographical
dispersion, low diagnostic rates, etc.) can be overcome by using ML techniques.
Objectives: This review aims to highlight the accomplishments of AI algorithms in the study
of rare diseases and to guide researchers on which strategies have proven to be the most beneficial.
Methods: The study will focus on a few rare diseases. The Orphanet categorization was used,
and only RDs with Orpha codes were considered. And will look at which AI methodologies have been
most successful in their research.
Results and discussion: ML techniques demonstrate that no single strategy excels
universally; success is dependent on unique tasks and resources. The complexity, interpretability, and
data requirements of models differ. While deep learning can capture complicated patterns, it may be
difficult to interpret, as opposed to simpler models such as logistic regression. There is a clear trade
off between model complexity and performance. Ensemble learning, like random forests, is resistant
to noisy data. Deep learning necessitates enormous computational resources. Tuning hyperparameters
is crucial, and technique selection should be guided by domain-specific factors.
Conclusion: In conclusion, from the standpoint of precision medicine, AI algorithms can help
to design individualized treatment plans by finding biomarkers linked with a specific rare disease. AI
systems that discover, forecast, and classify mutations can advance RDs diagnosis, raising these figures
and uncovering new disease causes and therapeutic targets.
The AI-mediated knowledge of RDs could considerably accelerate therapeutic development
